Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

XENCOR INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: $1B

Website

Clinical Trials

Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Ovarian Cancer
Endometrial Cancer
Ovarian Germ Cell Tumor
Germ Cell Tumor
Testicular Germ Cell Tumor

Interventions: Biological: XmAb541

First Posted Date: 2024-02-26

Last Posted Date: 2025-04-13

Lead Sponsor: Xencor, Inc.

Target Recruit Count: 212

Registration Number: NCT06276491

Locations: 🇺🇸
Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States

and more 6 locations

Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC

Phase 1

Recruiting

Conditions: Nonsquamous Non-small Cell Lung Cancer

Interventions: Combination Product: Pembrolizumab + Carboplatin + Pemetrexed
Combination Product: Vudalimab + Carboplatin + Pemetrexed

First Posted Date: 2023-12-15

Last Posted Date: 2024-12-04

Lead Sponsor: Xencor, Inc.

Target Recruit Count: 168

Registration Number: NCT06173505

Locations: 🇺🇸
Memorial Cancer Institute at Memorial Hospital West, Pembroke Pines, Florida, United States
🇺🇸
Midwestern Regional Medical Center, Zion, Illinois, United States
🇬🇷
Athens Medical Center, Athens, Greece

and more 40 locations

Multiple Ascending-Dose Study of XmAb®27564 in Patients With Psoriasis or Atopic Dermatitis

Phase 1

Active, not recruiting

Conditions: Psoriasis
Atopic Dermatitis

Interventions: Biological: XmAb27564
Biological: Placebo

First Posted Date: 2023-08-22

Last Posted Date: 2024-05-16

Lead Sponsor: Xencor, Inc.

Target Recruit Count: 128

Registration Number: NCT06005792

Locations: 🇺🇸
Unison Clinical Trials, Sherman Oaks, California, United States
🇺🇸
Clinical Trials Research Institute, Thousand Oaks, California, United States
🇺🇸
Driven Research, Coral Gables, Florida, United States

and more 4 locations

A Study of XmAb®662 as Monotherapy or in Combination With Pembrolizumab in Advanced Solid Tumors

Phase 1

Terminated

Conditions: Solid Tumors

Interventions: Biological: XmAb662
Biological: Keytruda® (pembrolizumab)

First Posted Date: 2023-08-18

Last Posted Date: 2024-08-23

Lead Sponsor: Xencor, Inc.

Target Recruit Count: 7

Registration Number: NCT05996445

Locations: 🇺🇸
Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸
University Of Virginia Comprehensive Cancer Center, Charlottesville, Virginia, United States

Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors

Phase 1

Active, not recruiting

Conditions: Melanoma Excluding Uveal Melanoma
Ovarian Cancer, Epithelial
Head and Neck Squamous Cell Carcinoma
Non-small Cell Lung Cancer, Squamous or Non-squamous
Renal Cell Carcinoma, Clear Cell
TNBC - Triple-Negative Breast Cancer
Colorectal Cancer
Castration-resistant Prostate Cancer
Urothelial Carcinoma

Interventions: Biological: XmAb®808
Biological: Keytruda® (pembrolizumab)

First Posted Date: 2022-10-18

Last Posted Date: 2025-03-28

Lead Sponsor: Xencor, Inc.

Target Recruit Count: 60

Registration Number: NCT05585034

Locations: 🇺🇸
UCLA Hematology/Oncology, Los Angeles, California, United States
🇺🇸
Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
🇺🇸
Florida Cancer Specialists, Sarasota, Florida, United States

and more 9 locations

Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

Phase 1

Recruiting

Conditions: Clear Cell Renal Cell Carcinoma

Interventions: Biological: XmAb819

First Posted Date: 2022-06-27

Last Posted Date: 2024-06-20

Lead Sponsor: Xencor, Inc.

Target Recruit Count: 95

Registration Number: NCT05433142

Locations: 🇺🇸
Department of Medical Oncology and Therapeutics Research, City of Hope, Duarte, California, United States
🇺🇸
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸
The University of Chicago Medical Center, Chicago, Illinois, United States

and more 5 locations

Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)

Phase 2

Terminated

Conditions: Diffuse Large-cell B-cell Lymphoma

Interventions: Biological: Plamotamab
Biological: Tafasitamab
Drug: Lenalidomide

First Posted Date: 2022-04-14

Last Posted Date: 2024-04-30

Lead Sponsor: Xencor, Inc.

Target Recruit Count: 3

Registration Number: NCT05328102

Locations: 🇺🇸
Swedish Cancer Center, Seattle, Washington, United States
🇫🇷
CHU de Rennes - Hopital de Pontchaillou, Rennes Cedex, France
🇪🇸
Hospital Universitario Virgen de las Nieves, Granada, Spain

A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies

Phase 2

Active, not recruiting

Conditions: Cervical Carcinoma
Endometrial Cancer
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Clear Cell Carcinoma
Ovarian Cancer

Interventions: Biological: vudalimab

First Posted Date: 2021-09-02

Last Posted Date: 2025-02-07

Lead Sponsor: Xencor, Inc.

Target Recruit Count: 150

Registration Number: NCT05032040

Locations: 🇺🇸
Arizona Oncology Associates, PC - NAHOA, Prescott, Arizona, United States
🇺🇸
UCSD Moores Cancer Center, La Jolla, California, United States
🇺🇸
Valkyrie Clinical Trials, Los Angeles, California, United States

and more 14 locations

XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 2

Active, not recruiting

Conditions: Metastatic Castration-Resistant Prostate Cancer

Interventions: Combination Product: vudalimab + cabazitaxel or docetaxel
Biological: vudalimab monotherapy
Combination Product: vudalimab + carboplatin + cabazitaxel
Combination Product: vudalimab + olaparib
Combination Product: vudalimab + docetaxel

First Posted Date: 2021-08-13

Last Posted Date: 2025-05-11

Lead Sponsor: Xencor, Inc.

Target Recruit Count: 72

Registration Number: NCT05005728

Locations: 🇺🇸
Alaska Oncology and Hematology, Anchorage, Alaska, United States
🇺🇸
Palo Verde Hematology Oncology, Glendale, Arizona, United States
🇺🇸
Mayo Clinic Hospital, Phoenix, Arizona, United States

and more 22 locations

Safety, Tolerability and PK of a Single Subcutaneous Injection of XmAb27564 in Healthy Volunteers

Phase 1

Completed

Conditions: Safety in Healthy Volunteers

Interventions: Drug: Placebo
Drug: XmAb27564

First Posted Date: 2021-04-23

Last Posted Date: 2023-03-01

Lead Sponsor: Xencor, Inc.

Target Recruit Count: 48

Registration Number: NCT04857866

Locations: 🇺🇸
ICON Early Phase Services, LLC, San Antonio, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy